Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats

BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Toshikazu, Zhang, Erquan, Omori, Ayaka, Kabwe, Jane, Kawai, Masako, Maruyama, Junko, Okada, Amphone, Yokochi, Ayumu, Sawada, Hirofumi, Mitani, Yoshihide, Maruyama, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/
https://www.ncbi.nlm.nih.gov/pubmed/34801000
http://dx.doi.org/10.1186/s12890-021-01710-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/
https://www.ncbi.nlm.nih.gov/pubmed/34801000
http://dx.doi.org/10.1186/s12890-021-01710-4

Ejemplares similares